Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$0.25
-13.7%
$4.79
$4.86
$37.50
$1.52M1.55467,323 shs1.97 million shs
Digirad Co. stock logo
DRAD
Digirad
$0.87
-2.3%
$3.58
$1.99
$8.84
$4.12M0.18485,592 shs23,082 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$0.26
+4.0%
$0.79
$0.22
$2.79
$2.81M0.98264,799 shs42,010 shs
Vaso Co. stock logo
VASO
Vaso
$0.27
-6.9%
$0.30
$0.19
$0.37
$54.19M2.03102,495 shs37,191 shs
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$0.00
$0.00
$0.00
$0.11
N/A0.082,455 shs1,030 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-14.95%-9.25%-43.98%-48.56%-94.37%
Digirad Co. stock logo
DRAD
Digirad
-2.32%-1.70%-4.96%-14.36%+8.12%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
+2.16%+13.94%-71.44%-74.77%-87.07%
Vaso Co. stock logo
VASO
Vaso
-4.08%-5.08%-5.88%-0.71%+19.66%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
0.00%+50.00%+50.00%+50.00%-99.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
N/AN/AN/AN/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
N/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$5.51M0.28N/AN/A$12.79 per share0.02
Digirad Co. stock logo
DRAD
Digirad
$114.18M0.04$1.25 per share0.69$10.30 per share0.08
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$0.67 per shareN/A
Vaso Co. stock logo
VASO
Vaso
$81.02M0.62$0.03 per share9.34$0.14 per share1.93
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$6.43M0.00N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-$18.11M-$279.28N/AN/AN/A-254.26%-173.61%-131.01%N/A
Digirad Co. stock logo
DRAD
Digirad
-$4.63M-$0.35N/AN/A-5.32%-3.75%-0.85%N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$10.06M-$1.93N/AN/AN/A-197.36%-144.22%5/20/2024 (Estimated)
Vaso Co. stock logo
VASO
Vaso
$4.80M$0.039.00N/A5.93%19.02%6.59%5/13/2024 (Estimated)
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
-$22.03MN/A0.00N/AN/AN/AN/AN/A

Latest VIVE, NDRA, VASO, CHFS, and DRAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
Vaso Co. stock logo
VASO
Vaso
N/A$0.01+$0.01$0.01N/A$21.92 million
3/28/2024Q4 2023
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A-$0.17-$0.17-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
$2.20254.34%N/AN/A N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
N/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/A
6.87
5.97
Digirad Co. stock logo
DRAD
Digirad
0.88
1.27
0.91
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
6.26
3.36
Vaso Co. stock logo
VASO
Vaso
N/A
1.50
1.45
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
65.06%
Digirad Co. stock logo
DRAD
Digirad
11.38%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%
Vaso Co. stock logo
VASO
Vaso
N/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/A

Insider Ownership

CompanyInsider Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
0.60%
Digirad Co. stock logo
DRAD
Digirad
12.49%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
4.80%
Vaso Co. stock logo
VASO
Vaso
44.56%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
5.73%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Nuwellis, Inc. stock logo
CHFS
Nuwellis
666.04 millionN/ANot Optionable
Digirad Co. stock logo
DRAD
Digirad
6184.76 millionN/ANot Optionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2111.04 million10.51 millionNot Optionable
Vaso Co. stock logo
VASO
Vaso
300185.63 million102.91 millionNot Optionable
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
4710.72 million10.11 millionNot Optionable

VIVE, NDRA, VASO, CHFS, and DRAD Headlines

SourceHeadline
5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 20285-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028
finance.yahoo.com - April 17 at 6:28 PM
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
finance.yahoo.com - April 15 at 7:58 AM
Viveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 10:31 AM
The Best Medical Billing Services of 2024The Best Medical Billing Services of 2024
business.com - January 19 at 10:31 PM
VIVE Viveve Medical, Inc.VIVE Viveve Medical, Inc.
seekingalpha.com - July 29 at 9:53 AM
InMode Expands Womens Health and Wellness Market Footprint through Acquisition of Viveve PatentsInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents
finance.yahoo.com - July 25 at 9:01 AM
VIVE - Viveve Medical, Inc.VIVE - Viveve Medical, Inc.
uk.finance.yahoo.com - June 14 at 7:59 PM
Viveve Medical, Inc. (VIVE)Viveve Medical, Inc. (VIVE)
finance.yahoo.com - February 24 at 8:19 AM
Viveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinenceViveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinence
pharmabiz.com - January 20 at 9:26 AM
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesdays Mid-Day SessionWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
msn.com - January 17 at 3:40 PM
Viveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finanznachrichten.de - January 17 at 10:39 AM
Viveve crashes ~60% as company decides to delist, explore sale after trial failsViveve crashes ~60% as company decides to delist, explore sale after trial fails
seekingalpha.com - January 17 at 10:39 AM
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finance.yahoo.com - January 17 at 10:39 AM
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial
finance.yahoo.com - January 17 at 10:39 AM
Why Is Viveve Medical (VIVE) Stock Down 69% Today?Why Is Viveve Medical (VIVE) Stock Down 69% Today?
investorplace.com - January 17 at 10:03 AM
Viveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call Transcript
insidermonkey.com - December 29 at 9:56 AM
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
finance.yahoo.com - December 15 at 10:21 AM
Viveve gets US patent for treating female stress urinary incontinenceViveve gets US patent for treating female stress urinary incontinence
pharmabiz.com - December 3 at 7:46 AM
Viveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finanznachrichten.de - December 1 at 12:46 PM
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finance.yahoo.com - December 1 at 12:46 PM
Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - November 13 at 7:01 PM
InvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate UpdateInvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate Update
markets.buffalonews.com - November 12 at 7:52 AM
Viveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finanznachrichten.de - November 10 at 4:16 PM
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 4:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuwellis logo

Nuwellis

NASDAQ:CHFS
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Digirad logo

Digirad

NASDAQ:DRAD
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. It also develops, sells, and maintains solid-state gamma cameras, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages real estate assets and investments. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.
ENDRA Life Sciences logo

ENDRA Life Sciences

NASDAQ:NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Vaso logo

Vaso

OTCMKTS:VASO
Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.
Viveve Medical logo

Viveve Medical

NASDAQ:VIVE
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.